| Today's Big NewsMay 2, 2023 |
| By James Waldron Johnson & Johnson may have gone quiet on getting further CAR-Ts into the clinic beyond the success of its Legend-partnered Carvykti, but that’s about to change. |
|
|
|
By Kevin Dunleavy With analysts expecting a free-fall in sales from COVID products, Pfizer pulled off a surprise with its first-quarter earnings report. Revenue for the period came in at $18.3 billion, routing the analyst consensus of $16.6 billion. With the performance, Pfizer reaffirmed its expectations for 2023 revenue to fall between $67 billion and $71 billion. |
By Angus Liu A New Jersey appellate court ruled that a group of insurers can’t use war as an argument to deny Merck coverage from the notorious NotPetya cyberattack in 2017. |
By Helen Floersh The scientists who used CRISPR to eliminate HIV in mice have done it again, this time with a three-pronged approach that nearly doubled their success rate. |
By Eric Sagonowsky Drug companies often have disagreements about the patents behind lucrative medicines, but it's highly unusual for the U.S. to take a top pharmaceutical company all the way to a trial. In the case over Gilead Sciences' PrEP drugs, that's exactly what's happening. |
By Andrea Park Less than two years after they first teamed up to distribute 3D-printed implants throughout the Asia-Pacific region—and only a few months after they expanded that partnership even further across the globe—Zimmer Biomet and Ossis are taking their relationship to the next level. |
By Heather Landi CVS Health has closed its $10.6 billion acquisition of Medicare-focused primary care player Oak Street Health as it moves forward aggressively on its strategy to expand beyond pharmacy into health services. |
Fierce podcasts Don't miss an episode |
| This week on "The Top Line," we talk about how Pfizer became the first company in Big Pharma history with $100 billion in sales. We also dive into a J&J data leak, Eli Lilly's manufacturing spending plan and more of this week's top headlines. |
|
|---|
|
|
|
July 18-19, 2023 | Jersey City, NJ
Connect with senior PR and communications leaders from big pharma, small-mid size pharma, biotech and more to gain insights and best practices on daily challenges in the industry. Save $500 when you Register Today! 
|
|
eBook Discover a game-changing approach to clinical research with Hybrid and Decentralized Clinical Trials (DCTs). Learn about the benefits, challenges, and key elements for success. Sponsored by: EvidentIQ |
Research What role do the Library and Legal teams play in the drug development pipeline at Lilly? An import one – find out how. Sponsored by: CCC |
Whitepaper This paper focuses on stakeholder engagement and how Medical Affairs teams’ responsibilities, goals, tools, and techniques are changing. Sponsored by: Blue Matter, strategic consultants in the life sciences |
Research Strategies for Optimal Site Selection and Feasibility Research in Novel Therapies and Geographies Sponsored by: H1 |
Whitepaper How can eConsent provide a more flexible approach to informed consent? Sponsored by: YPrime |
Whitepaper Preparation of critical process liquids and buffer components shifts resources away from core activities and can be filled with inefficiencies and risks that can increase time and costs across your workflow. Learn about the framework to help reduce your total costs beyond capital and operational expenditures and set a solid foundation for successful scale-up of buffer preparation. Sponsored by: Thermo Scientific Production Chemicals and Services |
Whitepaper Explore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
Whitepaper As sponsors increasingly look to CROs to support their clinical studies, making and addressing certain clinical supply considerations at the outset of the relationship can reduce the risk of potentially unforeseen impact to budget and time later. Discover key issues sponsors should consider to help their CRO or partner of choice better understand their clinical supply needs. Sponsored by: Catalent |
Whitepaper For sponsors, cost is a key concern when it comes to managing the supply of their clinical trials. A financial project analyst (FPA) is a specialized expert who can help control clinical supply costs and keep the project within budget. Explore the critical role that a Financial Project Analyst plays in clinical trial supply and budget management. Sponsored by: Catalent |
Whitepaper Learn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
Whitepaper Discover key considerations that every trial sponsor should know when navigating the complex clinical supply distribution landscape across Asia-Pacific. Sponsored by: Catalent |
Whitepaper How can specialized expertise help you optimize your clinical supply chain? Learn about the roles and responsibilities of unique experts such as clinical supply management, project management, and financial project analysis. Sponsored by: Catalent Clinical Supply |
Whitepaper Explore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
Whitepaper Planning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| May 1-3, 2023 | Jersey City, NJ |
|
|
| |
|
